Electroporation of a Non-Integrative DNA Nanovector for Efficient, Semi-Automated, GMP Manufacturing of CAR T Cell Therapies
Chimeric Antigen Receptors (CARs) have shown extraordinary efficacy in numerous clinical trials as an adoptive cell therapy to treat hematological malignancies. Still, CAR T therapy faces significant challenges, ranging from long lead times and expensive manufacturing to complicated vector engineering.
Read MoreMaxCyte® Enabled Innovative SARS-CoV-2 Vaccine Development
The pandemic caused by SARS-CoV-2 has killed millions worldwide and remains an incredible burden to global health care systems. Although vaccines have proven effective at preventing COVID-19-related mortality, they do not generate sterilizing immunity.
Read MoreHighly Efficient Homozygous Correction of the DYSF Gene in Miyoshi Myopathy Patient iPSCs by ssODN-Mediated Knockin
Human induced pluripotent stem cells (iPSCs) play an important role in disease modeling and drug screening, and have tremendous potential for regenerative medicine.
Read MoreGeneration of Heterozygous HLA-C iPSCs by ssODN Electroporation for Allogeneic Transplantation
Human-induced pluripotent stem cells (iPSCs) have tremendous potential for regenerative medicine. While there is an ongoing effort to recruit human leukocyte antigen (HLA) homozygous donors for allogeneic transplantation, a significant challenge with this approach is the susceptibility of these cells to host natural killer (NK) cell cytotoxicity.
Read MoreCase Study: Advancing an HIV Clinical Program for CCR5 Gene Disruption
Precision genome engineering requires technologies that allow efficient and reproducible delivery of DNA, mRNA and RNP-based reagents into a range of primary cells and stem cells. In addition, clinical gene editing requires a transfection platform that is GMP-compliant and scalable to accom- modate billions of cells in a single transfection.
Read MoreGene Knockin via Homology-directed Repair in Human iPSCs
Clinically validated and scalable MaxCyte® Flow Electroporation® Technology delivered ribonucleoprotein (RNP) and single-stranded oligonucleotide donor (ssODN) to induced pluripotent stem cells (iPSCs).
Read MoreCase Study: CRISPR mRNA & RNP Delivery
Demonstrating high efficiency delivery with low primary cell toxicity at clinical-scale — all critical parameters for commercial production of quality, clinically-active genetically engineered cells.
Read MoreEx Vivo Gene Correction in X-CGD Patient Stem Cells
Clinically-relevant Levels of gp91+ Cells in the Peripheral Blood and Bone Marrow Following Engraftment.
Read MoreOff-Target Effects of CRISPR-Cas9 Gene Editing in Human Hematopoietic Stem and Progenitor Cells
Here we share data characterizing genome integrity in clinically relevant human hematopoietic stem and progenitor cells (HSPCs) following transfection of CRISPR-Cas9 using MaxCyte® Flow Electroporation®.
Read MoreConditional Deletion of Large DNA Fragment in iPSCs by ssODN-Mediated Insertion of LoxP Sites without Antibiotic Selection
Cre-lox is an essential tool for creating conditional gene knockouts in human induced pluripotent stem cells (hiPSCs) for disease modeling and drug screening. Traditionally, both loxP sites are inserted into specific regions of the genome through homology-directed repair (HDR) prompted by delivery of CRISPR-Cas9 and a single donor template.
Read More